Acceleron Pharma Inc (NASDAQ:XLRN) SVP Christopher Rovaldi sold 11,000 shares of the business’s stock in a transaction on Friday, January 12th. The shares were sold at an average price of $45.00, for a total value of $495,000.00. Following the completion of the transaction, the senior vice president now owns 35,701 shares of the company’s stock, valued at $1,606,545. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Christopher Rovaldi also recently made the following trade(s):

  • On Wednesday, January 3rd, Christopher Rovaldi sold 2,266 shares of Acceleron Pharma stock. The shares were sold at an average price of $42.42, for a total value of $96,123.72.

Shares of Acceleron Pharma Inc (NASDAQ XLRN) opened at $44.99 on Thursday. Acceleron Pharma Inc has a twelve month low of $23.07 and a twelve month high of $46.93. The stock has a market capitalization of $2,036.48, a price-to-earnings ratio of -17.37 and a beta of 1.59.

Acceleron Pharma (NASDAQ:XLRN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.02. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The firm had revenue of $3.00 million during the quarter, compared to the consensus estimate of $3.52 million. During the same period in the prior year, the firm earned ($0.55) EPS. The firm’s quarterly revenue was up .0% compared to the same quarter last year. research analysts expect that Acceleron Pharma Inc will post -2.65 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. increased its holdings in Acceleron Pharma by 9.0% in the 2nd quarter. BlackRock Inc. now owns 4,005,228 shares of the biopharmaceutical company’s stock valued at $121,719,000 after purchasing an additional 330,635 shares in the last quarter. Vanguard Group Inc. increased its holdings in Acceleron Pharma by 6.1% in the 2nd quarter. Vanguard Group Inc. now owns 2,029,040 shares of the biopharmaceutical company’s stock valued at $61,663,000 after purchasing an additional 116,705 shares in the last quarter. Perceptive Advisors LLC increased its holdings in Acceleron Pharma by 127.2% in the 3rd quarter. Perceptive Advisors LLC now owns 1,616,259 shares of the biopharmaceutical company’s stock valued at $60,319,000 after purchasing an additional 905,000 shares in the last quarter. State Street Corp increased its holdings in Acceleron Pharma by 9.4% in the 2nd quarter. State Street Corp now owns 1,131,824 shares of the biopharmaceutical company’s stock valued at $34,386,000 after purchasing an additional 97,199 shares in the last quarter. Finally, Sectoral Asset Management Inc increased its holdings in Acceleron Pharma by 378.2% in the 2nd quarter. Sectoral Asset Management Inc now owns 604,499 shares of the biopharmaceutical company’s stock valued at $18,371,000 after purchasing an additional 478,099 shares in the last quarter. Hedge funds and other institutional investors own 85.70% of the company’s stock.

XLRN has been the subject of several analyst reports. HC Wainwright boosted their price target on Acceleron Pharma from $57.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, November 7th. Oppenheimer reiterated a “hold” rating on shares of Acceleron Pharma in a report on Monday, December 11th. Barclays boosted their price target on Acceleron Pharma from $42.00 to $50.00 and gave the company an “overweight” rating in a report on Wednesday, September 20th. ValuEngine downgraded Acceleron Pharma from a “hold” rating to a “sell” rating in a report on Friday, October 6th. Finally, Cann restated a “hold” rating on shares of Acceleron Pharma in a report on Monday, January 8th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have assigned a buy rating to the stock. Acceleron Pharma presently has a consensus rating of “Buy” and an average target price of $44.56.

ILLEGAL ACTIVITY WARNING: “Christopher Rovaldi Sells 11,000 Shares of Acceleron Pharma Inc (XLRN) Stock” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.dailypolitical.com/2018/01/18/christopher-rovaldi-sells-11000-shares-of-acceleron-pharma-inc-xlrn-stock.html.

Acceleron Pharma Company Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Insider Buying and Selling by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.